Olema Pharmaceuticals Inc (OLMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $662.30M
Last updated: Nov 17, 2026 at 11:06 AM ET
Olema Pharmaceuticals Inc (OLMA) Stock Forecast
Analysts expect Olema Pharmaceuticals (OLMA) to earn -$2.56 per share in the fiscal year ending Dec 31, 2026. Of 12 analysts, 11 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 7 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 1.92, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 16.7% |
| Buy | 9 | 75.0% |
| Hold | 1 | 8.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$2.56
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$2.90
- EPS consensus, revenue $19.98M
- Next report
- Mar 15, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.56 | -$3.13 to -$2.14 | 9 | N/A | N/A | 7 |
| Dec 31, 2027 | -$2.90 | -$3.49 to -$2.32 | 9 | $19.98M | N/A | 6 |
Quarterly Estimates
The EPS consensus rises from -$0.72 for the quarter ending Dec 31, 2026 to -$0.69 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.72 | -$0.76 to -$0.55 | 12 |
| Mar 31, 2027 | -$0.69 | -$0.81 to -$0.62 | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 17 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 7 |
| Fiscal year ending Dec 31, 2027 | 1 | 7 |
| Quarter ending Mar 31, 2027 | 0 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.42.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.56 | -$2.38 | -$2.38 | -$2.42 | -$2.42 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.90 | -$2.64 | -$2.64 | -$2.69 | -$2.69 | N/A |
| Quarter ending Mar 31, 2027 | -$0.69 | -$0.61 | -$0.61 | -$0.65 | -$0.65 | N/A |
Frequently Asked Questions About OLMA
What is the OLMA stock forecast?
Consensus analyst estimates put Olema Pharmaceuticals's EPS at -$2.56 for the fiscal year ending Dec 31, 2026. The consensus rating from 12 analysts is Buy.
How do analysts rate OLMA stock?
Of 12 analysts covering Olema Pharmaceuticals, 2 rate it Strong Buy, 9 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from OLMA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.56, with estimates from -$3.13 to -$2.14 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.90, with estimates from -$3.49 to -$2.32 from 9 analysts.
What revenue do analysts expect from Olema Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $19.98M.
How many analysts cover OLMA?
12 analysts rate Olema Pharmaceuticals stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
OLMA pages: Overview, Earnings, Forecast, Financials, Competitors